<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026818</url>
  </required_header>
  <id_info>
    <org_study_id>13086</org_study_id>
    <secondary_id>H6D-EW-LVIK</secondary_id>
    <nct_id>NCT01026818</nct_id>
  </id_info>
  <brief_title>A Study of Tadalafil After Radical Prostatectomy</brief_title>
  <acronym>REACTT</acronym>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 Months in Subjects Undergoing Bilateral Nerve-Sparing Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include patients with localized prostate cancer who experience erectile
      dysfunction following bilateral nerve-sparing radical prostatectomy. Patients will be
      randomly assigned to three treatment arms: Tadalafil 5 mg once a day, Tadalafil 20 mg on
      demand (prior to anticipated sexual activity), and placebo. Patients will stay on therapy for
      9 months and after withdrawal of medication for 6 weeks, patients will be evaluated for
      recovery of unassisted erectile function (without medication). An open-label extension for
      three months will evaluate the responsiveness of all patients to Tadalafil 5 mg once a day.
      Further objectives are to evaluate the treatment satisfaction of the respective therapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire</measure>
    <time_frame>Month 10.5</time_frame>
    <description>Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Score of Greater Than or Equal to 22 in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain</measure>
    <time_frame>Month 9 and Month 13.5</time_frame>
    <description>Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in the International Index of Erectile Function- Erectile Function (IIEF-EF) Total Score</measure>
    <time_frame>Randomization (Baseline), Months 9 and 10.5 and 13.5</time_frame>
    <description>Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF) Domains (Intercourse Satisfaction Domain, Orgasmic Function Domain, Sexual Desire Domain, Overall Satisfaction Domain)</measure>
    <time_frame>Randomization (Baseline), Months 9 and 10.5 and 13.5</time_frame>
    <description>Self-reported overall satisfaction during past 4 weeks. Orgasmic function score is sum of Questions (Q)9 and 10 of IIEF. Scores range from 0 (no sexual stimulation or intercourse) to 5 (high orgasm) for each Q, total 0 to 10. Sexual desire score is sum of Q11 and 12 of IIEF. Scores range from 1 (low/no desire) to 5 (high desire) for each Q, total 2 to 10. Intercourse satisfaction score is sum of Q6, 7 and 8 of IIEF. Scores range from 0 (no attempts for Q6, did not attempt intercourse for Q7 and no intercourse for Q8) to 5 (high satisfaction) for each Q, total 0 to 15. Overall satisfaction score is sum of Q13 and 14 of IIEF. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each Q, total 2 to 10. Higher total scores for each domain indicate higher function. MMRM analysis was used to calculate LS mean and 95% CI. LS mean values are adjusted for baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire Mean Score</measure>
    <time_frame>Months 9 and 13.5</time_frame>
    <description>The EDITS questionnaire is a validated questionnaire consisting of 11 questions evaluating self-reported satisfaction with the erectile dysfunction (ED) treatment. Responses were based on the experiences during the previous 4 weeks. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS mean score was obtained by adding each individual result for all questions, dividing by the number of questions answered. The mean scores range from 0 (extremely low treatment satisfaction) to 4 (extremely high satisfaction). The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Self Esteem and Relationship (SEAR) Questionnaire Score</measure>
    <time_frame>Randomization (Baseline), Months 9 and 13.5</time_frame>
    <description>The SEAR questionnaire is a participant-reported measure of psychosocial outcomes in men with erectile dysfunction (ED). It consists of 14 items. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The total scores for sexual relationship domain range from 8-40 with higher scores indicating better relationship. Self-Esteem subdomain contains items 9 through 12 rated on a scale of 1 (no/low self-esteem) to 5 (high self-esteem). Total scores for Self-Esteem subscale range from 4-20 with higher scores indicating higher self-esteem. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Questions (GAQ) Question 1 at Month 9</measure>
    <time_frame>Month 9</time_frame>
    <description>GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Question (GAQ) Question 1 at Month 13.5</measure>
    <time_frame>Month 13.5</time_frame>
    <description>GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Question (GAQ) Question 2 at Month 9</measure>
    <time_frame>Month 9</time_frame>
    <description>GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Question (GAQ) Question 2 at Month 13.5</measure>
    <time_frame>Month 13.5</time_frame>
    <description>GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Erectile Function (REF) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Erectile Function (REF) at Month 2</measure>
    <time_frame>Month 2</time_frame>
    <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Erectile Function (REF) at Month 5</measure>
    <time_frame>Month 5</time_frame>
    <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Erectile Function (REF) at Month 9</measure>
    <time_frame>Month 9</time_frame>
    <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Erectile Function (REF) at Month 10.5</measure>
    <time_frame>Month 10.5</time_frame>
    <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Erectile Function (REF) at Month 13.5</measure>
    <time_frame>Month 13.5</time_frame>
    <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 'Yes' Answers to Questions 1 to 5 of the Sexual Encounter Profile (SEP)</measure>
    <time_frame>Randomization (Baseline), Months 9 and 10.5 and 13.5</time_frame>
    <description>Participant-assessed diary has 5 questions: Question (Q)1: erection achievement, Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 'Yes' Answers to Morning Erections</measure>
    <time_frame>Randomization (Baseline), Month 10.5</time_frame>
    <description>The participants were asked to complete the morning erections diary every morning during the 4-week period before randomization and during the 6-week, Drug-Free, Washout Period. Data presented are the changes in the participant's percentage of &quot;yes&quot; responses relative to the number of days the question was answered during treatment. The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline morning erections frequency, age group and country.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Morning Erections Question (SMEQ) Score at Month 2</measure>
    <time_frame>Month 2</time_frame>
    <description>Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ (&quot;Do you ever wake up with an erection&quot;) using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Morning Erections Question (SMEQ) Score at Month 9</measure>
    <time_frame>Month 9</time_frame>
    <description>Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ (&quot;Do you ever wake up with an erection&quot;) using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Morning Erections Question (SMEQ) Score at Month 13.5</measure>
    <time_frame>Month 13.5</time_frame>
    <description>Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ (&quot;Do you ever wake up with an erection&quot;) using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 26-item Expanded Prostate Cancer Index Composite (EPIC-26) Questionnaire Score</measure>
    <time_frame>Randomization (Baseline), Months 9 and 13.5</time_frame>
    <description>EPIC-26 (participants) contains 26 items and 5 domains: Urinary Incontinence (Items 1-4), Urinary Irritative/Obstructive (Items 5-8), Bowel (Items 10-15), Sexual (Items 16-21), and Hormonal (Items 22-26). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0 to 100 scale for each domain, with higher scores representing better health-related quality of life. Responses are based on experiences during the previous 4 weeks. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Penile Length and Girth</measure>
    <time_frame>Randomization (Baseline), Month 9</time_frame>
    <description>Measurements were performed with the penis in the flaccid state. The stretched penile length was measured from the tip of the glans to the pubopenile skin junction while applying tension to maximally stretch the penis. The penile circumference at midshaft was measured. All measurements were taken with a paper ruler to the nearest 0.5 centimeter (cm). The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline, age group and country.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">583</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Tadalafil daily [5 milligrams (mg)]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil on demand (20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Administered by mouth for 9 months</description>
    <arm_group_label>Tadalafil daily [5 milligrams (mg)]</arm_group_label>
    <arm_group_label>Tadalafil on demand (20 mg)</arm_group_label>
    <other_name>Cialis</other_name>
    <other_name>LY450190</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by mouth, daily or on demand for 9 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scheduled to undergo Bilateral nerve-sparing radical prostatectomy (BNSRP) for
             organ-confined, non-metastatic prostate cancer

          -  have a normal preoperative erectile function score of more or equal to 22 at
             screening(as evaluated by International Index of Erectile Function - Erectile Function
             domain (IIEF-EF))

          -  develop Erectile Dysfunction (ED) (defined as the consistent inability to achieve
             and/or maintain an erection sufficient to permit satisfactory sexual intercourse)
             after surgery

          -  have an interest in resuming sexual activity as soon as possible after surgery and
             anticipate having the same adult female sexual partner during the study

          -  agree not to use any other treatment for ED, including herbal and over-the-counter
             (OTC) medications, during the study

          -  does not require the initiation of adjuvant therapy for prostate cancer

        Exclusion Criteria:

          -  history of ED

          -  have received previous or current treatment with tadalafil or any other
             Phosphodiesterase Type 5 (PDE5) inhibitor

          -  have undergone, or plan to undergo, radiation or hormonal therapy for prostate cancer

          -  have a history of prostatic surgery or prostatic physical treatments

          -  have a history of diabetes mellitus

          -  have a history of galactose intolerance, lapp lactase deficiency, or glucose-galactose
             malabsorption

          -  have clinically significant renal insufficiency as determined by the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2W 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Herne</city>
        <zip>44627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Acquavivadellefonti</city>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Perugia</city>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>S-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kielce</city>
        <zip>25-734</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aravaca</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Luzern</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Middlesbrough</city>
        <state>Cleveland</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stevenage</city>
        <state>Herts</state>
        <zip>SG4 7NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Withington</city>
        <state>Manchester</state>
        <zip>M20 9BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <results_first_submitted>September 10, 2013</results_first_submitted>
  <results_first_submitted_qc>September 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 14, 2013</results_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>Radical Prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study consisted of a 6-week screening period including the time of bilateral nerve-sparing radical prostatectomy (BNSRP) surgery, a 9-month, randomized Double-Blind (DB), Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label (OL) Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Screen - BNSRP</title>
          <description>BNSRP surgery during Screening Period.</description>
        </group>
        <group group_id="P2">
          <title>Tadalafil 5 mg OaD</title>
          <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
        </group>
        <group group_id="P3">
          <title>Tadalafil 20 mg PRN</title>
          <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="583"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="423"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>DB Treatment Period (Month 0 - 9)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="143"/>
                <participants group_id="P4" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="143"/>
                <participants group_id="P4" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Drug-Free Washout Period (Month 9-10.5)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>OL Period (Month 10.5 - 13.5)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="112"/>
                <participants group_id="P4" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Tadalafil 5 mg OaD</title>
          <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
        </group>
        <group group_id="B2">
          <title>Tadalafil 20 mg PRN</title>
          <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="139"/>
            <count group_id="B2" value="143"/>
            <count group_id="B3" value="141"/>
            <count group_id="B4" value="423"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="5.07"/>
                    <measurement group_id="B2" value="57.5" spread="5.91"/>
                    <measurement group_id="B3" value="57.6" spread="5.69"/>
                    <measurement group_id="B4" value="57.9" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire</title>
        <description>Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.</description>
        <time_frame>Month 10.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had IIEF-EF Total Scores measurement at Month 10.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire</title>
          <description>Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had IIEF-EF Total Scores measurement at Month 10.5.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="16.9"/>
                    <measurement group_id="O3" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A sample size of 412 randomized participants provided 84% power to detect a 20% difference in the proportions for the 3 treatment groups. The sample size allowed for a 20% withdrawal during the study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <p_value_desc>The Type I error was controlled for multiplicity using a Bonferroni-Hommel procedure. First the largest p-value for the odds ratio to placebo was tested at the 5% level and in case of no rejection the second p-value was tested at the 2.5% level.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model included terms for treatment group, country, and age group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A sample size of 412 randomized participants provided 84% power to detect a 20% difference in the proportions for the 3 treatment groups. The sample size allowed for a 20% withdrawal during the study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.704</p_value>
            <p_value_desc>The Type I error was controlled for multiplicity using a Bonferroni-Hommel procedure. First the largest p-value for the odds ratio to placebo was tested at the 5% level and in case of no rejection the second p-value was tested at the 2.5% level.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model included terms for treatment group, country, and age group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Score of Greater Than or Equal to 22 in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain</title>
        <description>Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.</description>
        <time_frame>Month 9 and Month 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had IIEF-EF Total Scores measurements at Months 9 and 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Score of Greater Than or Equal to 22 in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain</title>
          <description>Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had IIEF-EF Total Scores measurements at Months 9 and 13.5.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="19.7"/>
                    <measurement group_id="O3" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4"/>
                    <measurement group_id="O2" value="33.1"/>
                    <measurement group_id="O3" value="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>P-value is for Month 9.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model included terms for treatment group, country, and age group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>3.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.210</p_value>
            <p_value_desc>P-value is for Month 9.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model included terms for treatment group, country, and age group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>P-value is for Month 13.5.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model included terms for treatment group, country, and age group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.259</p_value>
            <p_value_desc>P-value is for Month 13.5.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model included terms for treatment group, country, and age group.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in the International Index of Erectile Function- Erectile Function (IIEF-EF) Total Score</title>
        <description>Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
        <time_frame>Randomization (Baseline), Months 9 and 10.5 and 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least one post-baseline IIEF-EF Total Scores measurement at Months 9, 10.5 and 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in the International Index of Erectile Function- Erectile Function (IIEF-EF) Total Score</title>
          <description>Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
          <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least one post-baseline IIEF-EF Total Scores measurement at Months 9, 10.5 and 13.5.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.73" lower_limit="5.73" upper_limit="9.73"/>
                    <measurement group_id="O2" value="6.53" lower_limit="4.56" upper_limit="8.50"/>
                    <measurement group_id="O3" value="4.93" lower_limit="2.88" upper_limit="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" lower_limit="4.22" upper_limit="8.25"/>
                    <measurement group_id="O2" value="5.76" lower_limit="3.78" upper_limit="7.73"/>
                    <measurement group_id="O3" value="5.98" lower_limit="3.92" upper_limit="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.60" lower_limit="8.39" upper_limit="12.80"/>
                    <measurement group_id="O2" value="9.78" lower_limit="7.63" upper_limit="11.92"/>
                    <measurement group_id="O3" value="8.97" lower_limit="6.74" upper_limit="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is for Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>2.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>4.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <p_value_desc>P-value is for Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean differences</param_type>
            <param_value>1.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>3.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.802</p_value>
            <p_value_desc>P-value is for Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.79</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.830</p_value>
            <p_value_desc>P-value is for Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.23</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.184</p_value>
            <p_value_desc>P-value is for Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>1.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>4.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <p_value_desc>P-value is for Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.54</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF) Domains (Intercourse Satisfaction Domain, Orgasmic Function Domain, Sexual Desire Domain, Overall Satisfaction Domain)</title>
        <description>Self-reported overall satisfaction during past 4 weeks. Orgasmic function score is sum of Questions (Q)9 and 10 of IIEF. Scores range from 0 (no sexual stimulation or intercourse) to 5 (high orgasm) for each Q, total 0 to 10. Sexual desire score is sum of Q11 and 12 of IIEF. Scores range from 1 (low/no desire) to 5 (high desire) for each Q, total 2 to 10. Intercourse satisfaction score is sum of Q6, 7 and 8 of IIEF. Scores range from 0 (no attempts for Q6, did not attempt intercourse for Q7 and no intercourse for Q8) to 5 (high satisfaction) for each Q, total 0 to 15. Overall satisfaction score is sum of Q13 and 14 of IIEF. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each Q, total 2 to 10. Higher total scores for each domain indicate higher function. MMRM analysis was used to calculate LS mean and 95% CI. LS mean values are adjusted for baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
        <time_frame>Randomization (Baseline), Months 9 and 10.5 and 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least one post-baseline IIEF domain scores measurements at Months 9, 10.5 and 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF) Domains (Intercourse Satisfaction Domain, Orgasmic Function Domain, Sexual Desire Domain, Overall Satisfaction Domain)</title>
          <description>Self-reported overall satisfaction during past 4 weeks. Orgasmic function score is sum of Questions (Q)9 and 10 of IIEF. Scores range from 0 (no sexual stimulation or intercourse) to 5 (high orgasm) for each Q, total 0 to 10. Sexual desire score is sum of Q11 and 12 of IIEF. Scores range from 1 (low/no desire) to 5 (high desire) for each Q, total 2 to 10. Intercourse satisfaction score is sum of Q6, 7 and 8 of IIEF. Scores range from 0 (no attempts for Q6, did not attempt intercourse for Q7 and no intercourse for Q8) to 5 (high satisfaction) for each Q, total 0 to 15. Overall satisfaction score is sum of Q13 and 14 of IIEF. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each Q, total 2 to 10. Higher total scores for each domain indicate higher function. MMRM analysis was used to calculate LS mean and 95% CI. LS mean values are adjusted for baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
          <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least one post-baseline IIEF domain scores measurements at Months 9, 10.5 and 13.5.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Orgasmic function - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" lower_limit="1.98" upper_limit="3.55"/>
                    <measurement group_id="O2" value="2.48" lower_limit="1.70" upper_limit="3.26"/>
                    <measurement group_id="O3" value="2.39" lower_limit="1.59" upper_limit="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasmic function - Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" lower_limit="2.13" upper_limit="3.76"/>
                    <measurement group_id="O2" value="2.48" lower_limit="1.68" upper_limit="3.28"/>
                    <measurement group_id="O3" value="2.48" lower_limit="1.66" upper_limit="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasmic function - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" lower_limit="2.75" upper_limit="4.39"/>
                    <measurement group_id="O2" value="2.90" lower_limit="2.10" upper_limit="3.70"/>
                    <measurement group_id="O3" value="3.42" lower_limit="2.59" upper_limit="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual desire - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.18" upper_limit="1.12"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.18" upper_limit="1.11"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.15" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual desire - Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" lower_limit="0.14" upper_limit="1.07"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.20" upper_limit="1.11"/>
                    <measurement group_id="O3" value="0.55" lower_limit="0.08" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual desire - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.56" upper_limit="1.52"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.42" upper_limit="1.35"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.46" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intercourse satisfaction - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" lower_limit="2.90" upper_limit="4.88"/>
                    <measurement group_id="O2" value="3.50" lower_limit="2.52" upper_limit="4.48"/>
                    <measurement group_id="O3" value="2.96" lower_limit="1.95" upper_limit="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intercourse satisfaction - Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" lower_limit="2.19" upper_limit="4.22"/>
                    <measurement group_id="O2" value="2.81" lower_limit="1.81" upper_limit="3.81"/>
                    <measurement group_id="O3" value="2.72" lower_limit="1.69" upper_limit="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intercourse satisfaction - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" lower_limit="3.65" upper_limit="5.75"/>
                    <measurement group_id="O2" value="4.08" lower_limit="3.05" upper_limit="5.10"/>
                    <measurement group_id="O3" value="4.14" lower_limit="3.08" upper_limit="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall satisfaction - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.38" upper_limit="1.56"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.35" upper_limit="1.51"/>
                    <measurement group_id="O3" value="0.78" lower_limit="0.18" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall satisfaction - Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="0.05" upper_limit="1.23"/>
                    <measurement group_id="O2" value="0.48" lower_limit="-0.10" upper_limit="1.06"/>
                    <measurement group_id="O3" value="0.72" lower_limit="0.12" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall satisfaction - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.87" upper_limit="2.13"/>
                    <measurement group_id="O2" value="1.57" lower_limit="0.96" upper_limit="2.19"/>
                    <measurement group_id="O3" value="1.52" lower_limit="0.88" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.340</p_value>
            <p_value_desc>P-value is for orgasmic function - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.821</p_value>
            <p_value_desc>P-value is for orgasmic function - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.268</p_value>
            <p_value_desc>P-value is for orgasmic function - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.998</p_value>
            <p_value_desc>P-value is for orgasmic function - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.728</p_value>
            <p_value_desc>P-value is for orgasmic function - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.203</p_value>
            <p_value_desc>P-value is for orgasmic function - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.950</p_value>
            <p_value_desc>P-value is for sexual desire - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.950</p_value>
            <p_value_desc>P-value is for sexual desire - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.792</p_value>
            <p_value_desc>P-value is for sexual desire - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.631</p_value>
            <p_value_desc>P-value is for sexual desire - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.691</p_value>
            <p_value_desc>P-value is for sexual desire - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.801</p_value>
            <p_value_desc>P-value is for sexual desire - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <p_value_desc>P-value is for intercourse satisfaction - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.274</p_value>
            <p_value_desc>P-value is for intercourse satisfaction - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.359</p_value>
            <p_value_desc>P-value is for intercourse satisfaction - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.863</p_value>
            <p_value_desc>P-value is for intercourse satisfaction - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.314</p_value>
            <p_value_desc>P-value is for intercourse satisfaction - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.910</p_value>
            <p_value_desc>P-value is for intercourse satisfaction - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.532</p_value>
            <p_value_desc>P-value is for overall satisfaction - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.620</p_value>
            <p_value_desc>P-value is for overall satisfaction - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.792</p_value>
            <p_value_desc>P-value is for overall satisfaction - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <p_value_desc>P-value is for overall satisfaction - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.955</p_value>
            <p_value_desc>P-value is for overall satisfaction - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.868</p_value>
            <p_value_desc>P-value is for overall satisfaction - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire Mean Score</title>
        <description>The EDITS questionnaire is a validated questionnaire consisting of 11 questions evaluating self-reported satisfaction with the erectile dysfunction (ED) treatment. Responses were based on the experiences during the previous 4 weeks. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS mean score was obtained by adding each individual result for all questions, dividing by the number of questions answered. The mean scores range from 0 (extremely low treatment satisfaction) to 4 (extremely high satisfaction). The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
        <time_frame>Months 9 and 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had EDITS mean scores measurements at Months 9 and 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire Mean Score</title>
          <description>The EDITS questionnaire is a validated questionnaire consisting of 11 questions evaluating self-reported satisfaction with the erectile dysfunction (ED) treatment. Responses were based on the experiences during the previous 4 weeks. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS mean score was obtained by adding each individual result for all questions, dividing by the number of questions answered. The mean scores range from 0 (extremely low treatment satisfaction) to 4 (extremely high satisfaction). The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had EDITS mean scores measurements at Months 9 and 13.5.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.11" lower_limit="2.00" upper_limit="2.42"/>
                    <measurement group_id="O2" value="2.11" lower_limit="1.92" upper_limit="2.30"/>
                    <measurement group_id="O3" value="1.88" lower_limit="1.67" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" lower_limit="2.31" upper_limit="2.77"/>
                    <measurement group_id="O2" value="2.38" lower_limit="2.17" upper_limit="2.59"/>
                    <measurement group_id="O3" value="2.25" lower_limit="2.03" upper_limit="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-value is for Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <p_value_desc>P-value is for Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>P-value is for Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.316</p_value>
            <p_value_desc>P-value is for Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Self Esteem and Relationship (SEAR) Questionnaire Score</title>
        <description>The SEAR questionnaire is a participant-reported measure of psychosocial outcomes in men with erectile dysfunction (ED). It consists of 14 items. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The total scores for sexual relationship domain range from 8-40 with higher scores indicating better relationship. Self-Esteem subdomain contains items 9 through 12 rated on a scale of 1 (no/low self-esteem) to 5 (high self-esteem). Total scores for Self-Esteem subscale range from 4-20 with higher scores indicating higher self-esteem. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
        <time_frame>Randomization (Baseline), Months 9 and 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least 1 post-baseline SEAR scores measurement at Months 9 and 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Self Esteem and Relationship (SEAR) Questionnaire Score</title>
          <description>The SEAR questionnaire is a participant-reported measure of psychosocial outcomes in men with erectile dysfunction (ED). It consists of 14 items. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The total scores for sexual relationship domain range from 8-40 with higher scores indicating better relationship. Self-Esteem subdomain contains items 9 through 12 rated on a scale of 1 (no/low self-esteem) to 5 (high self-esteem). Total scores for Self-Esteem subscale range from 4-20 with higher scores indicating higher self-esteem. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
          <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least 1 post-baseline SEAR scores measurement at Months 9 and 13.5.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sexual relationship - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" lower_limit="2.87" upper_limit="6.68"/>
                    <measurement group_id="O2" value="3.50" lower_limit="1.61" upper_limit="5.38"/>
                    <measurement group_id="O3" value="3.02" lower_limit="1.09" upper_limit="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual relationship - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.90" lower_limit="4.79" upper_limit="9.00"/>
                    <measurement group_id="O2" value="6.68" lower_limit="4.62" upper_limit="8.74"/>
                    <measurement group_id="O3" value="6.72" lower_limit="4.62" upper_limit="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-esteem - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" lower_limit="-0.31" upper_limit="1.87"/>
                    <measurement group_id="O2" value="0.79" lower_limit="-0.29" upper_limit="1.87"/>
                    <measurement group_id="O3" value="0.51" lower_limit="-0.61" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-esteem - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" lower_limit="0.54" upper_limit="2.81"/>
                    <measurement group_id="O2" value="1.72" lower_limit="0.61" upper_limit="2.83"/>
                    <measurement group_id="O3" value="1.62" lower_limit="0.47" upper_limit="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.086</p_value>
            <p_value_desc>P-value is for sexual relationship - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>1.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>3.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.637</p_value>
            <p_value_desc>P-value is for sexual relationship - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.885</p_value>
            <p_value_desc>P-value is for sexual relationship - Month 13.5</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.972</p_value>
            <p_value_desc>P-value is for sexual relationship - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.34</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.621</p_value>
            <p_value_desc>P-value is for self-esteem - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.598</p_value>
            <p_value_desc>P-value is for self-esteem - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.923</p_value>
            <p_value_desc>P-value is for self-esteem - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.857</p_value>
            <p_value_desc>P-value is for self-esteem - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment Questions (GAQ) Question 1 at Month 9</title>
        <description>GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
        <time_frame>Month 9</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had GAQ Q1 assessed at Month 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment Questions (GAQ) Question 1 at Month 9</title>
          <description>GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had GAQ Q1 assessed at Month 9.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment Question (GAQ) Question 1 at Month 13.5</title>
        <description>GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
        <time_frame>Month 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had GAQ Q1 assessed at Month 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment Question (GAQ) Question 1 at Month 13.5</title>
          <description>GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had GAQ Q1 assessed at Month 13.5.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment Question (GAQ) Question 2 at Month 9</title>
        <description>GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
        <time_frame>Month 9</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had GAQ Q2 assessed at Month 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment Question (GAQ) Question 2 at Month 9</title>
          <description>GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had GAQ Q2 assessed at Month 9.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment Question (GAQ) Question 2 at Month 13.5</title>
        <description>GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
        <time_frame>Month 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had GAQ Q2 assessed at Month 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment Question (GAQ) Question 2 at Month 13.5</title>
          <description>GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had GAQ Q2 assessed at Month 13.5.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Erectile Function (REF) at Baseline</title>
        <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Erectile Function (REF) at Baseline</title>
          <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
          <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REF = 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Erectile Function (REF) at Month 2</title>
        <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
        <time_frame>Month 2</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Erectile Function (REF) at Month 2</title>
          <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
          <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REF = 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Erectile Function (REF) at Month 5</title>
        <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
        <time_frame>Month 5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Erectile Function (REF) at Month 5</title>
          <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
          <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 5.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REF = 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Erectile Function (REF) at Month 9</title>
        <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
        <time_frame>Month 9</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Erectile Function (REF) at Month 9</title>
          <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
          <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 9.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REF = 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Erectile Function (REF) at Month 10.5</title>
        <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
        <time_frame>Month 10.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 10.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Erectile Function (REF) at Month 10.5</title>
          <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
          <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 10.5.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REF = 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Erectile Function (REF) at Month 13.5</title>
        <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
        <time_frame>Month 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Erectile Function (REF) at Month 13.5</title>
          <description>The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)</description>
          <population>All randomized participants who received at least 1 dose of study drug and had REF assessed at Month 13.5.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REF = 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REF = 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ‘Yes’ Answers to Questions 1 to 5 of the Sexual Encounter Profile (SEP)</title>
        <description>Participant-assessed diary has 5 questions: Question (Q)1: erection achievement, Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
        <time_frame>Randomization (Baseline), Months 9 and 10.5 and 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least 1 post-baseline SEP questions answered at Months 9, 10.5 and 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ‘Yes’ Answers to Questions 1 to 5 of the Sexual Encounter Profile (SEP)</title>
          <description>Participant-assessed diary has 5 questions: Question (Q)1: erection achievement, Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
          <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least 1 post-baseline SEP questions answered at Months 9, 10.5 and 13.5.</population>
          <units>percentage of &quot;yes&quot; responses</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1 - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.41" lower_limit="58.29" upper_limit="76.54"/>
                    <measurement group_id="O2" value="63.88" lower_limit="55.32" upper_limit="72.44"/>
                    <measurement group_id="O3" value="52.54" lower_limit="43.62" upper_limit="61.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1 - Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.78" lower_limit="58.05" upper_limit="77.50"/>
                    <measurement group_id="O2" value="64.24" lower_limit="55.06" upper_limit="73.41"/>
                    <measurement group_id="O3" value="58.86" lower_limit="49.15" upper_limit="68.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1 - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.16" lower_limit="77.82" upper_limit="94.51"/>
                    <measurement group_id="O2" value="79.79" lower_limit="71.93" upper_limit="87.65"/>
                    <measurement group_id="O3" value="75.27" lower_limit="66.93" upper_limit="83.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2 - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.00" lower_limit="35.22" upper_limit="52.78"/>
                    <measurement group_id="O2" value="34.29" lower_limit="26.03" upper_limit="42.56"/>
                    <measurement group_id="O3" value="27.67" lower_limit="19.11" upper_limit="36.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2 - Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.81" lower_limit="31.21" upper_limit="50.40"/>
                    <measurement group_id="O2" value="34.99" lower_limit="25.91" upper_limit="44.08"/>
                    <measurement group_id="O3" value="36.26" lower_limit="26.67" upper_limit="45.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2 - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.48" lower_limit="53.87" upper_limit="73.09"/>
                    <measurement group_id="O2" value="56.07" lower_limit="46.91" upper_limit="65.24"/>
                    <measurement group_id="O3" value="50.11" lower_limit="40.56" upper_limit="59.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3 - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.67" lower_limit="25.47" upper_limit="41.86"/>
                    <measurement group_id="O2" value="24.09" lower_limit="16.36" upper_limit="31.82"/>
                    <measurement group_id="O3" value="21.61" lower_limit="13.62" upper_limit="29.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3 - Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.75" lower_limit="19.92" upper_limit="37.57"/>
                    <measurement group_id="O2" value="23.01" lower_limit="14.65" upper_limit="31.37"/>
                    <measurement group_id="O3" value="28.52" lower_limit="19.68" upper_limit="37.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3 - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.41" lower_limit="42.80" upper_limit="62.02"/>
                    <measurement group_id="O2" value="45.83" lower_limit="36.63" upper_limit="55.04"/>
                    <measurement group_id="O3" value="40.75" lower_limit="31.18" upper_limit="50.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4 - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.17" lower_limit="18.93" upper_limit="33.40"/>
                    <measurement group_id="O2" value="18.15" lower_limit="11.31" upper_limit="24.99"/>
                    <measurement group_id="O3" value="14.30" lower_limit="7.25" upper_limit="21.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4 - Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.94" lower_limit="9.66" upper_limit="24.23"/>
                    <measurement group_id="O2" value="11.74" lower_limit="4.84" upper_limit="18.64"/>
                    <measurement group_id="O3" value="18.88" lower_limit="11.54" upper_limit="26.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4 - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.08" lower_limit="32.99" upper_limit="51.18"/>
                    <measurement group_id="O2" value="35.62" lower_limit="26.88" upper_limit="44.37"/>
                    <measurement group_id="O3" value="30.56" lower_limit="21.48" upper_limit="39.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5 - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.42" lower_limit="18.29" upper_limit="32.55"/>
                    <measurement group_id="O2" value="17.73" lower_limit="10.99" upper_limit="24.47"/>
                    <measurement group_id="O3" value="14.04" lower_limit="7.09" upper_limit="20.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5 - Month 10.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.26" lower_limit="9.21" upper_limit="23.31"/>
                    <measurement group_id="O2" value="10.52" lower_limit="3.85" upper_limit="17.19"/>
                    <measurement group_id="O3" value="19.11" lower_limit="12.00" upper_limit="26.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5 - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.81" lower_limit="31.82" upper_limit="49.81"/>
                    <measurement group_id="O2" value="34.96" lower_limit="26.31" upper_limit="43.62"/>
                    <measurement group_id="O3" value="29.38" lower_limit="20.39" upper_limit="38.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value is for Q1 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>14.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.92</ci_lower_limit>
            <ci_upper_limit>25.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <p_value_desc>P-value is for Q1 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>11.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>22.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.148</p_value>
            <p_value_desc>P-value is for Q1 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>8.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.18</ci_lower_limit>
            <ci_upper_limit>21.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.373</p_value>
            <p_value_desc>P-value is for Q1 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>5.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.48</ci_lower_limit>
            <ci_upper_limit>17.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value is for Q1 - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>10.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>20.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.357</p_value>
            <p_value_desc>P-value is for Q1 - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>4.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.12</ci_lower_limit>
            <ci_upper_limit>14.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value is for Q2 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>16.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.68</ci_lower_limit>
            <ci_upper_limit>26.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.212</p_value>
            <p_value_desc>P-value is for Q2 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>6.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.80</ci_lower_limit>
            <ci_upper_limit>17.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.461</p_value>
            <p_value_desc>P-value is for Q2 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>4.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.58</ci_lower_limit>
            <ci_upper_limit>16.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.835</p_value>
            <p_value_desc>P-value is for Q2 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-1.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.16</ci_lower_limit>
            <ci_upper_limit>10.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>P-value is for Q2 - Month13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>13.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>25.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.326</p_value>
            <p_value_desc>P-value is for Q2 - Month13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>5.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.97</ci_lower_limit>
            <ci_upper_limit>17.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>P-value is for Q3 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>12.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.98</ci_lower_limit>
            <ci_upper_limit>22.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.621</p_value>
            <p_value_desc>P-value is for Q3 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>2.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.38</ci_lower_limit>
            <ci_upper_limit>12.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.968</p_value>
            <p_value_desc>P-value is for Q3 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.03</ci_lower_limit>
            <ci_upper_limit>11.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.327</p_value>
            <p_value_desc>P-value is for Q3 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-5.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.55</ci_lower_limit>
            <ci_upper_limit>5.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <p_value_desc>P-value is for Q3 - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>11.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>24.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.415</p_value>
            <p_value_desc>P-value is for Q3 - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>5.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.17</ci_lower_limit>
            <ci_upper_limit>17.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>P-value is for Q4 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>11.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.79</ci_lower_limit>
            <ci_upper_limit>20.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.394</p_value>
            <p_value_desc>P-value is for Q4 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>3.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.03</ci_lower_limit>
            <ci_upper_limit>12.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.684</p_value>
            <p_value_desc>P-value is for Q4 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-1.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.28</ci_lower_limit>
            <ci_upper_limit>7.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.126</p_value>
            <p_value_desc>P-value is for Q4 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-7.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.30</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.061</p_value>
            <p_value_desc>P-value is for Q4 - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>11.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>23.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <p_value_desc>P-value is for Q4 - Month13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>5.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.83</ci_lower_limit>
            <ci_upper_limit>16.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-value is for Q5 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>11.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.38</ci_lower_limit>
            <ci_upper_limit>20.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <p_value_desc>P-value is for Q5 - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>3.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.11</ci_lower_limit>
            <ci_upper_limit>12.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.537</p_value>
            <p_value_desc>P-value is for Q5 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-2.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.92</ci_lower_limit>
            <ci_upper_limit>6.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <p_value_desc>P-value is for Q5 - Month 10.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-8.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.48</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.061</p_value>
            <p_value_desc>P-value is for Q5 - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>11.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>23.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.353</p_value>
            <p_value_desc>P-value is for Q5 - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>5.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.23</ci_lower_limit>
            <ci_upper_limit>17.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ‘Yes’ Answers to Morning Erections</title>
        <description>The participants were asked to complete the morning erections diary every morning during the 4-week period before randomization and during the 6-week, Drug-Free, Washout Period. Data presented are the changes in the participant's percentage of “yes” responses relative to the number of days the question was answered during treatment. The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline morning erections frequency, age group and country.</description>
        <time_frame>Randomization (Baseline), Month 10.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had morning erection question answered at Baseline and Month 10.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ‘Yes’ Answers to Morning Erections</title>
          <description>The participants were asked to complete the morning erections diary every morning during the 4-week period before randomization and during the 6-week, Drug-Free, Washout Period. Data presented are the changes in the participant's percentage of “yes” responses relative to the number of days the question was answered during treatment. The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline morning erections frequency, age group and country.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had morning erection question answered at Baseline and Month 10.5.</population>
          <units>percentage of &quot;yes&quot; response</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.92" lower_limit="1.45" upper_limit="16.39"/>
                    <measurement group_id="O2" value="12.16" lower_limit="5.16" upper_limit="19.16"/>
                    <measurement group_id="O3" value="14.04" lower_limit="6.74" upper_limit="21.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included treatment, baseline, age group, and country.</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-5.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.32</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included treatment, baseline, age group, and country.</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-1.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.99</ci_lower_limit>
            <ci_upper_limit>5.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Morning Erections Question (SMEQ) Score at Month 2</title>
        <description>Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ (“Do you ever wake up with an erection”) using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).</description>
        <time_frame>Month 2</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had SMEQ measurement at Month 2</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Morning Erections Question (SMEQ) Score at Month 2</title>
          <description>Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ (“Do you ever wake up with an erection”) using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had SMEQ measurement at Month 2</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes, regularly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less frequently than in the past</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only occasionally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Morning Erections Question (SMEQ) Score at Month 9</title>
        <description>Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ (&quot;Do you ever wake up with an erection&quot;) using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).</description>
        <time_frame>Month 9</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had SMEQ measurement at Month 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Morning Erections Question (SMEQ) Score at Month 9</title>
          <description>Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ (&quot;Do you ever wake up with an erection&quot;) using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had SMEQ measurement at Month 9.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes, regularly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less frequently than in the past</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only occasionally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Morning Erections Question (SMEQ) Score at Month 13.5</title>
        <description>Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ (&quot;Do you ever wake up with an erection&quot;) using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).</description>
        <time_frame>Month 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had SMEQ measurement at Month 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Morning Erections Question (SMEQ) Score at Month 13.5</title>
          <description>Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ (&quot;Do you ever wake up with an erection&quot;) using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had SMEQ measurement at Month 13.5.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes, regularly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less frequently than in the past</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only occasionally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 26-item Expanded Prostate Cancer Index Composite (EPIC-26) Questionnaire Score</title>
        <description>EPIC-26 (participants) contains 26 items and 5 domains: Urinary Incontinence (Items 1-4), Urinary Irritative/Obstructive (Items 5-8), Bowel (Items 10-15), Sexual (Items 16-21), and Hormonal (Items 22-26). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0 to 100 scale for each domain, with higher scores representing better health-related quality of life. Responses are based on experiences during the previous 4 weeks. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
        <time_frame>Randomization (Baseline), Months 9 and 13.5</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least 1 post-baseline EPIC-26 scores measurement at Month 9 and Month 13.5.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 26-item Expanded Prostate Cancer Index Composite (EPIC-26) Questionnaire Score</title>
          <description>EPIC-26 (participants) contains 26 items and 5 domains: Urinary Incontinence (Items 1-4), Urinary Irritative/Obstructive (Items 5-8), Bowel (Items 10-15), Sexual (Items 16-21), and Hormonal (Items 22-26). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0 to 100 scale for each domain, with higher scores representing better health-related quality of life. Responses are based on experiences during the previous 4 weeks. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</description>
          <population>All randomized participants who received at least 1 dose of study drug, had baseline and at least 1 post-baseline EPIC-26 scores measurement at Month 9 and Month 13.5.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urinary Incontinence - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.08" lower_limit="29.31" upper_limit="38.86"/>
                    <measurement group_id="O2" value="31.12" lower_limit="26.74" upper_limit="35.51"/>
                    <measurement group_id="O3" value="30.59" lower_limit="25.85" upper_limit="35.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Incontinence - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.41" lower_limit="32.56" upper_limit="42.26"/>
                    <measurement group_id="O2" value="35.54" lower_limit="31.10" upper_limit="39.97"/>
                    <measurement group_id="O3" value="35.44" lower_limit="30.65" upper_limit="40.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Irritative/Obstructive - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.83" lower_limit="11.54" upper_limit="16.12"/>
                    <measurement group_id="O2" value="13.28" lower_limit="11.19" upper_limit="15.37"/>
                    <measurement group_id="O3" value="12.26" lower_limit="10.01" upper_limit="14.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Irritative/Obstructive - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.86" lower_limit="11.53" upper_limit="16.20"/>
                    <measurement group_id="O2" value="13.82" lower_limit="11.70" upper_limit="15.94"/>
                    <measurement group_id="O3" value="12.30" lower_limit="0.01" upper_limit="14.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.94" lower_limit="3.71" upper_limit="8.17"/>
                    <measurement group_id="O2" value="6.27" lower_limit="4.22" upper_limit="8.33"/>
                    <measurement group_id="O3" value="6.48" lower_limit="4.31" upper_limit="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" lower_limit="4.67" upper_limit="9.08"/>
                    <measurement group_id="O2" value="6.49" lower_limit="4.46" upper_limit="8.52"/>
                    <measurement group_id="O3" value="6.78" lower_limit="4.61" upper_limit="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.53" lower_limit="21.64" upper_limit="33.42"/>
                    <measurement group_id="O2" value="20.66" lower_limit="15.27" upper_limit="26.06"/>
                    <measurement group_id="O3" value="17.98" lower_limit="12.14" upper_limit="23.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.55" lower_limit="30.03" upper_limit="43.06"/>
                    <measurement group_id="O2" value="32.58" lower_limit="26.60" upper_limit="38.56"/>
                    <measurement group_id="O3" value="33.37" lower_limit="26.95" upper_limit="39.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hormonal - Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="-0.81" upper_limit="4.26"/>
                    <measurement group_id="O2" value="2.72" lower_limit="0.36" upper_limit="5.08"/>
                    <measurement group_id="O3" value="-0.18" lower_limit="-2.67" upper_limit="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hormonal - Month 13.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="0.10" upper_limit="4.87"/>
                    <measurement group_id="O2" value="2.92" lower_limit="0.76" upper_limit="5.08"/>
                    <measurement group_id="O3" value="3.01" lower_limit="0.67" upper_limit="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <p_value_desc>P-value is for Urinary Incontinence - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>3.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.82</ci_lower_limit>
            <ci_upper_limit>8.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.841</p_value>
            <p_value_desc>P-value is for Urinary Incontinence - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.69</ci_lower_limit>
            <ci_upper_limit>5.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.474</p_value>
            <p_value_desc>P-value is for Urinary Incontinence - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>1.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.45</ci_lower_limit>
            <ci_upper_limit>7.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.971</p_value>
            <p_value_desc>P-value is for Urinary Incontinence - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.21</ci_lower_limit>
            <ci_upper_limit>5.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.236</p_value>
            <p_value_desc>P-value is for Urinary Irritative/Obstructive - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>1.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>4.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.429</p_value>
            <p_value_desc>P-value is for Urinary Irritative/Obstructive - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>1.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.52</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.252</p_value>
            <p_value_desc>P-value is for Urinary Irritative/Obstructive - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>1.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>4.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.251</p_value>
            <p_value_desc>P-value is for Urinary Irritative/Obstructive - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>1.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.671</p_value>
            <p_value_desc>P-value is for Bowel - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.868</p_value>
            <p_value_desc>P-value is for Bowel - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.64</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.938</p_value>
            <p_value_desc>P-value is for Bowel - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.37</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.813</p_value>
            <p_value_desc>P-value is for Bowel - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.69</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is for Sexual - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>9.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.10</ci_lower_limit>
            <ci_upper_limit>15.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <p_value_desc>P-value is for Sexual - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>2.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.63</ci_lower_limit>
            <ci_upper_limit>9.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.406</p_value>
            <p_value_desc>P-value is for Sexual - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>3.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.34</ci_lower_limit>
            <ci_upper_limit>10.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.832</p_value>
            <p_value_desc>P-value is for Sexual - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.11</ci_lower_limit>
            <ci_upper_limit>6.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.197</p_value>
            <p_value_desc>P-value is for Hormonal - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>1.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>4.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <p_value_desc>P-value is for Hormonal - Month 9.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>2.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>5.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.692</p_value>
            <p_value_desc>P-value is for Hormonal - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.16</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.943</p_value>
            <p_value_desc>P-value is for Hormonal - Month 13.5.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p&lt;0.10).</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.65</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Penile Length and Girth</title>
        <description>Measurements were performed with the penis in the flaccid state. The stretched penile length was measured from the tip of the glans to the pubopenile skin junction while applying tension to maximally stretch the penis. The penile circumference at midshaft was measured. All measurements were taken with a paper ruler to the nearest 0.5 centimeter (cm). The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline, age group and country.</description>
        <time_frame>Randomization (Baseline), Month 9</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had penile measurements at Baseline and Month 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 5 mg OaD</title>
            <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 20 mg PRN</title>
            <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-Week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Penile Length and Girth</title>
          <description>Measurements were performed with the penis in the flaccid state. The stretched penile length was measured from the tip of the glans to the pubopenile skin junction while applying tension to maximally stretch the penis. The penile circumference at midshaft was measured. All measurements were taken with a paper ruler to the nearest 0.5 centimeter (cm). The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline, age group and country.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had penile measurements at Baseline and Month 9.</population>
          <units>millimeter (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Length</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" lower_limit="-5.54" upper_limit="2.47"/>
                    <measurement group_id="O2" value="-7.26" lower_limit="-11.04" upper_limit="-3.49"/>
                    <measurement group_id="O3" value="-5.73" lower_limit="-9.68" upper_limit="-1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Girth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-3.09" upper_limit="3.15"/>
                    <measurement group_id="O2" value="0.82" lower_limit="-2.11" upper_limit="3.75"/>
                    <measurement group_id="O3" value="-2.34" lower_limit="-5.43" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>P-value is for length.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline, age group and country.</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>4.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>7.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.413</p_value>
            <p_value_desc>P-value is for length.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline, age group and country.</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>-1.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.20</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.112</p_value>
            <p_value_desc>P-value is for girth.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline, age group and country.</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>2.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>5.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>P-value is for girth.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included terms for treatment, baseline, age group and country.</method_desc>
            <param_type>LS Mean Differences</param_type>
            <param_value>3.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>6.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Screen - BNSRP</title>
          <description>Had bilateral nerve-sparing radical prostatectomy (BNSRP) surgery during Screening Period.</description>
        </group>
        <group group_id="E2">
          <title>Tadalafil 5 mg OaD (Double-Blind Period/Washout Period)</title>
          <description>Tadalafil 5 mg once a day (OaD) + Placebo as required/on demand (PRN) for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period.</description>
        </group>
        <group group_id="E3">
          <title>Tadalafil 20 mg PRN (Double-Blind Period/Washout Period)</title>
          <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period.</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Double-Blind Period/Washout Period)</title>
          <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period.</description>
        </group>
        <group group_id="E5">
          <title>Tadalafil 5 mg OaD (Open-Label Period)</title>
          <description>Tadalafil 5 mg OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
        </group>
        <group group_id="E6">
          <title>Tadalfil 20 mg PRN (Open-Label Period)</title>
          <description>Placebo OaD + Tadalafil 20 mg PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
        </group>
        <group group_id="E7">
          <title>Placebo (Open-Label Period)</title>
          <description>Placebo OaD + Placebo PRN for 9 months during Double-Blind, Placebo-Controlled Treatment Period, followed by a 6-week, Drug-Free Washout Period, and a 3-month, Open-Label Period with tadalafil 5 mg OaD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA(15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>Event resulted in death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail bed inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA(15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="139"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Androgen deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypoprolactinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Eyelid pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="583"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tongue geographic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="583"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Anastomotic complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Haematuria traumatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Incision site blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Incision site complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Optic nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Testicular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood luteinising hormone decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood selenium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood selenium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Oestradiol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urine output increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Vitamin d deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Bone lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="583"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="143"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Orgasm abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="583"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Genital discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pelvic discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Penile curvature</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Solar lentigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arthroscopic surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Bladder catheterisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Circumcision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dental implantation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Eyelid operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lipoma excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Polypectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Wart excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

